Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
People affected by two different privacy breaches at AT&T can claim up to $7,500 if they file a claim soon. Peter is a writer and editor for the CNET How-To team. He has been covering technology, ...
Sommige resultaten zijn verborgen omdat ze mogelijk niet toegankelijk zijn voor u.
Niet-toegankelijke resultaten weergeven